NSCLC ADENOCARCINOMA
Clinical trials for NSCLC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NSCLC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for NSCLC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug MGC028 enters first human tests for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (like lung, bile duct, pancreas, or colon cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink or control the cancer…
Matched conditions: NSCLC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 17, 2026 09:20 UTC
-
New drug combo targets genetic weakness in tough cancers
Disease control Recruiting nowThis early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main g…
Matched conditions: NSCLC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC